<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01332175</url>
  </required_header>
  <id_info>
    <org_study_id>EK-1600</org_study_id>
    <nct_id>NCT01332175</nct_id>
  </id_info>
  <brief_title>The Effects of Provent® on Obstructive Sleep Apnea During Continuous Positive Airway Pressure Therapy Withdrawal</brief_title>
  <official_title>The Effects of Provent® on Obstructive Sleep Apnea During Continuous Positive Airway Pressure Therapy Withdrawal: a Randomised Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomised, placebo-controlled trial of continuous positive airway pressure therapy (CPAP)
      versus Provent® and Placebo-Provent® to define the effects of Provent® on the severity of
      obstructive sleep apnea, daytime symptoms as well as on measures of cardiovascular risk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomised, placebo-controlled trial of Provent® versus Placebo-Provent® versus continuous
      positive airway pressure therapy (CPAP) to define the effects of Provent® on the severity of
      obstructive sleep apnea, daytime symptoms as well as on measures of cardiovascular risk in
      patients with obstructive sleep apnea.

      Patients successfully treated with CPAP will be randomised to one of three arms for a
      duration of 2 weeks:

        1. Withdraw CPAP and use Provent®

        2. Withdraw CPAP and use Placebo-Provent®

        3. Continue treatment with CPAP
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep apnoea severity, daytime symptoms of sleep apnoea</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>2 weeks</time_frame>
    <description>Comparison of changes in systolic and diastolic blood pressure from baseline to follow-up at 2 weeks.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Provent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Provent</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CPAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Provent®</intervention_name>
    <description>Nightly use of Provent® versus Placebo-Provent® versus CPAP</description>
    <arm_group_label>Provent</arm_group_label>
    <arm_group_label>Placebo-Provent</arm_group_label>
    <arm_group_label>CPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo-Provent®</intervention_name>
    <description>Nightly use of Provent® versus Placebo-Provent® versus CPAP</description>
    <arm_group_label>Placebo-Provent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CPAP</intervention_name>
    <description>Nightly use of Provent® versus Placebo-Provent® versus CPAP</description>
    <arm_group_label>CPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Objectively confirmed obstructive sleep apnoea (at the time of original diagnosis)
             with an oxygen desaturation index (ODI, &gt;4% dips) of between 10 and 50/h and an ESS of
             &gt;10 (these thresholds will exclude subjects with borderline and very severe forms of
             OSA in whom there may be a disproportionate treatment effect).

          2. Currently &gt;10/h oxygen desaturations (&gt;4% dips) during an ambulatory nocturnal pulse
             oximetry performed at the end of a 4-night period without CPAP.

          3. Treated with NCPAP for more than 12 months, minimum compliance 4h per night.

          4. Current ESS &lt; 10.

          5. Written informed consent.

        Exclusion criteria:

          1. Previous ventilatory failure (awake resting arterial oxygen saturation &lt;93% or
             arterial PCO2 &gt; 6kPa).

          2. Unstable, untreated coronary or peripheral artery disease, severe arterial
             hypertension (&gt;180/110mmHg).

          3. Previously diagnosed with Cheyne-Stokes breathing.

          4. Current professional driver.

          5. Any sleep related accident.

          6. Age &lt;20 or &gt;75 years at trial entry.

          7. History of chronic nasal obstruction.

          8. Mental or physical disability precluding informed consent or compliance with the
             protocol .

          9. Non-feasible trial follow-up (for example, distance from follow-up centre, physical
             inability).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm Kohler, MD, Leading Physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Division of Pneumology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cantonal Hospital Munsterlingen, Departement of Internal Medicine, Pulmonary Division</name>
      <address>
        <city>Munsterlingen</city>
        <zip>8596</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich, Pulmonary Division</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital, Oxford Centre for Respiratory Medicine</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2011</study_first_submitted>
  <study_first_submitted_qc>April 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2011</study_first_posted>
  <last_update_submitted>August 15, 2012</last_update_submitted>
  <last_update_submitted_qc>August 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

